Avance Clinical Unveils Dedicated CNS Center of Excellence for Expert Clinical Trial Services in Neuroscience

Distinguished Leadership

Leading the center is Dr. Francesco Bibbiani, whose appointment as Vice President & Therapeutic Area Head, CNS Center of Excellence represents a significant strategic acquisition. Bibbiani brings over 25 years of CNS clinical development experience from senior leadership roles at Neurogene, Dyne Therapeutics, Ultragenyx, PTC Therapeutics, and Eisai Inc. His expertise spans Phase I through pivotal trials across multiple CNS conditions including Parkinson’s disease, Huntington’s disease, neuromuscular disorders, and epilepsy, complemented by board certification in neurology and 25+ peer-reviewed publications.

“CNS drug development presents complex clinical trial challenges, particularly for biotech companies with innovative mechanisms and constrained resources,” said Bibbiani. “Our center integrates specialized CNS clinical expertise with proven operational excellence, enabling sponsors to execute high-quality trials efficiently from first-in-human studies through pivotal Phase III programs.”

Strategic Partnership Model

Designed exclusively for biotech companies, the center operates as a true partnership that strategically incorporates Australia’s unparalleled regulatory advantages across all trial designs. Whether conducting Early Phase studies exclusively in Australia or managing global multi-regional trials, the center maximizes the Australian advantage through accelerated startup timelines, streamlined regulatory pathways, and strategic program structuring that optimizes the 43.5% R&D tax incentive. This approach transforms Australia’s unique benefits into competitive advantages for both Australia-only early phase trials and international Late phase programs spanning multiple geographies.

Key Differentiators

Avance Clinical’s key differentiators include exclusive biotech focus across all trial phases, involving thorough program analyses and strategic advice by subject matter experts through specialized centers of excellence, in-house regulatory affairs teams, access to over 2,000 specialized clinical sites globally, and proprietary GlobalReady process enabling seamless transition from Early Phase Australian studies to multi-regional Late phase programs.